ASX · ALC.AX
Alcidion Group Limited
A$0.11-A$0.01 (-4.35%)
Alcidion Group Limited’s quoted price sits in the lower half of its reported 52-week range, 24.14% below the high.
Loading market information…
ASX · PCK.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 03:47 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
PainChek Limited’s quoted price sits in the lower half of its reported 52-week range, 84.8% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
PainChek Limited’s next earnings report is currently expected on Mar 3, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow PainChek Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
PainChek Limited specializes in the creation and commercialization of mobile medical applications designed for individual pain assessment. Their core product, PainChek, employs smartphone and tablet cameras to record video, which is then analyzed in real-time by facial recognition software to detect the presence of pain. This technology is particularly beneficial for patients suffering from dementia. The company, which operates from its headquarters in Sydney, Australia, rebranded as PainChek Limited in January 2018, having previously been known as ePAT Technologies Ltd.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:19 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.11-A$0.01 (-4.35%)
Alcidion Group Limited’s quoted price sits in the lower half of its reported 52-week range, 24.14% below the high.
A$0.35+A$0.02 (+4.55%)
Recce Pharmaceuticals Ltd’s quoted price sits in the lower half of its reported 52-week range, 52.74% below the high.
A$0.26+A$0.01 (+2.0%)
Mach7 Technologies Limited’s quoted price sits in the lower half of its reported 52-week range, 62.77% below the high.
A$0.18+A$0.00 (0.0%)
Singular Health Group Ltd’s quoted price sits in the lower half of its reported 52-week range, 40.0% below the high.
A$0.26-A$0.01 (-1.92%)
Alterity Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 67.52% below the high.
A$0.43+A$0.05 (+12.34%)
Cyclopharm Limited’s quoted price sits in the lower half of its reported 52-week range, 66.47% below the high.
A$0.03-A$0.01 (-15.38%)
Micro-X Limited’s quoted price sits in the lower half of its reported 52-week range, 71.3% below the high.
A$0.07+A$0.00 (+1.41%)
Beamtree Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 68.0% below the high.
